IL140665A0 - Antihypersensitive combination of valsartan and calcium channel blocker - Google Patents

Antihypersensitive combination of valsartan and calcium channel blocker

Info

Publication number
IL140665A0
IL140665A0 IL14066599A IL14066599A IL140665A0 IL 140665 A0 IL140665 A0 IL 140665A0 IL 14066599 A IL14066599 A IL 14066599A IL 14066599 A IL14066599 A IL 14066599A IL 140665 A0 IL140665 A0 IL 140665A0
Authority
IL
Israel
Prior art keywords
hypertension
diabetic
renal
pharmaceutically acceptable
primary
Prior art date
Application number
IL14066599A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22352165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL140665(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL140665A0 publication Critical patent/IL140665A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Steroid Compounds (AREA)
IL14066599A 1998-07-10 1999-07-09 Antihypersensitive combination of valsartan and calcium channel blocker IL140665A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11389398A 1998-07-10 1998-07-10
PCT/EP1999/004842 WO2000002543A2 (fr) 1998-07-10 1999-07-09 Methode de traitement et composition pharmaceutique

Publications (1)

Publication Number Publication Date
IL140665A0 true IL140665A0 (en) 2002-02-10

Family

ID=22352165

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14066599A IL140665A0 (en) 1998-07-10 1999-07-09 Antihypersensitive combination of valsartan and calcium channel blocker
IL140665A IL140665A (en) 1998-07-10 2001-01-01 Use of a combination of compounds containing valsartan and amlodipine in the preparation of drugs for the treatment and prevention of diabetes associated with hypertension
IL213926A IL213926A0 (en) 1998-07-10 2011-07-04 Use of combination compositions comprising valsartan and amlodipine in the preparation of medicaments for the treatment and prevention of diabetes associated with hypertension

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL140665A IL140665A (en) 1998-07-10 2001-01-01 Use of a combination of compounds containing valsartan and amlodipine in the preparation of drugs for the treatment and prevention of diabetes associated with hypertension
IL213926A IL213926A0 (en) 1998-07-10 2011-07-04 Use of combination compositions comprising valsartan and amlodipine in the preparation of medicaments for the treatment and prevention of diabetes associated with hypertension

Country Status (31)

Country Link
EP (3) EP1096932B1 (fr)
JP (1) JP2002520274A (fr)
KR (2) KR100550167B1 (fr)
CN (2) CN1733307A (fr)
AT (1) ATE371448T1 (fr)
AU (1) AU753486B2 (fr)
BE (1) BE2016C011I2 (fr)
BR (1) BR9912021A (fr)
CA (2) CA2678722C (fr)
CY (4) CY1107779T1 (fr)
CZ (2) CZ299429B6 (fr)
DE (2) DE69936992T2 (fr)
DK (2) DK1096932T3 (fr)
ES (2) ES2289814T3 (fr)
FR (1) FR16C0008I2 (fr)
HU (1) HU229383B1 (fr)
ID (1) ID27664A (fr)
IL (3) IL140665A0 (fr)
LU (2) LU91358I2 (fr)
NL (2) NL300290I2 (fr)
NO (2) NO331802B1 (fr)
NZ (2) NZ509260A (fr)
PL (1) PL194604B1 (fr)
PT (2) PT2322174E (fr)
RU (3) RU2450813C2 (fr)
SG (1) SG142116A1 (fr)
SI (2) SI1096932T1 (fr)
SK (1) SK285863B6 (fr)
TR (1) TR200100062T2 (fr)
WO (1) WO2000002543A2 (fr)
ZA (1) ZA200100232B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ509260A (en) 1998-07-10 2003-09-26 Novartis Ag Pharmaceutical composition containing valsartan and a calcium channel blocker
ATE524176T1 (de) * 1998-12-23 2011-09-15 Novartis Pharma Gmbh Valsartan tablette
EP1197223B1 (fr) * 1999-04-28 2005-02-16 Takeda Pharmaceutical Company Limited Preventifs / remedes / inhibiteurs de progression pour retinopathie simplex ou retinopathie preproliferante
WO2001005428A1 (fr) * 1999-07-21 2001-01-25 Takeda Chemical Industries, Ltd. Methodes preventives contre la recurrence d'une insuffisance cerebrovasculaire, et agents destines a ameliorer des troubles causes par une insuffisance cerebrovasculaire et a inhiber leur evolution
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
PL353199A1 (en) 1999-08-30 2003-11-03 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
WO2001062740A1 (fr) * 2000-02-25 2001-08-30 South Alabama Medical Science Foundation Analogues de mibefradil et leur utilisation
WO2001062741A1 (fr) * 2000-02-25 2001-08-30 South Alabama Medical Science Foundation Derives de tetrahydronaphtalene et leur utilisation
IL152081A0 (en) * 2000-04-12 2003-05-29 Novartis Ag Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
DE10018401A1 (de) 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
WO2002053147A1 (fr) * 2000-12-29 2002-07-11 Osmotica Corp. Composition pharmaceutique destinee au traitement de la maladie cerebrovasculaire cognitive
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
EP1448190A2 (fr) * 2001-10-18 2004-08-25 Novartis AG Sels comprenant un at1-recepteur antagoniste et un agent cardio-vasculaire
US20030180712A1 (en) * 2002-03-20 2003-09-25 Biostratum Ab Inhibition of the beta3 subunit of L-type Ca2+ channels
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
CA2525970C (fr) 2003-05-15 2011-03-22 Roskamp Research, Llc Utilisation de nilvadipine comme moyen de reduire le depot de substances amyloides, la neurotoxicite de substances amyloides et la microgliose
US20070054947A1 (en) * 2003-05-16 2007-03-08 Cohn Jay N Pharmaceutical composition comprising valsartan
RU2255740C2 (ru) * 2003-07-02 2005-07-10 Научно-исследовательский институт кардиологии Томского научного центра СО РАМН Способ подбора дозы дилтиазема для лечения больных постинфарктным кардиосклерозом с недостаточностью кровообращения 2 функционального класса
US20050065094A1 (en) 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
WO2005053687A1 (fr) * 2003-11-25 2005-06-16 Novartis Ag Combinaison de composes organiques
US20050187262A1 (en) * 2004-01-12 2005-08-25 Grogan Donna R. Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
CN100364532C (zh) * 2004-09-30 2008-01-30 江苏恒瑞医药股份有限公司 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物
EP1874311B1 (fr) 2005-04-15 2011-10-05 Research & Innovation S.p.A. Methode pour prevenir, retarder ou inverser la progression de pathologies associees a un depot amyloide anormal
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
GB0520405D0 (en) * 2005-10-07 2005-11-16 Imp College Innovations Ltd Biological agents and method
RU2008122712A (ru) * 2005-11-08 2009-12-20 Новартис АГ (CH) Комбинация органических соединений
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
RU2329805C2 (ru) * 2006-08-28 2008-07-27 Илья Николаевич Медведев Способ стабилизации эндотелиальной выстилки сосудов у больных метаболическим синдромом
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
RU2338527C1 (ru) * 2007-02-26 2008-11-20 Илья Николаевич Медведев Способ коррекции высокой эндотелиоцитемии у лиц с метаболическим синдромом
TWI500422B (zh) 2007-10-05 2015-09-21 Alzheimer S Inst Of America Inc 以（－）－尼代地平（ｎｉｌｖａｄｉｐｉｎｅ）對映異構物減低類澱粉沉積、類澱粉神經毒性及微神經膠細胞增生之方法
CN101433536A (zh) * 2007-11-12 2009-05-20 北京瑞康医药技术有限公司 含有烟酸氨氯地平和沙坦类药物的治疗组合物
JP2011507973A (ja) * 2007-12-31 2011-03-10 ルピン・リミテッド アムロジピンとバルサルタンとの医薬組成物
US20100137403A1 (en) * 2008-07-10 2010-06-03 Scott Malstrom Method for enhancing cognition or inhibiting cognitive decline
RU2382644C1 (ru) * 2008-11-05 2010-02-27 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гипертрофии левого желудочка у больных ибс в сочетании с гипертонической болезнью
RU2398581C1 (ru) * 2009-05-28 2010-09-10 Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс Федерального агентства по высокотехнологичной медицинской помощи (ФГУ РКНПК Росмедтехнологий) Способ лечения больных гипертрофической кардиомиопатией
SI2536396T1 (sl) 2010-02-16 2017-01-31 KRKA, tovarna zdravil, d.d.,Novo mesto Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
BR112013025222B8 (pt) 2011-04-12 2020-05-05 Boryung Pharm composição farmacêutica anti-hipertensiva e uso da mesma
AR089645A1 (es) 2011-08-12 2014-09-10 Boehringer Ingelheim Vetmed Particula multicapas de sabor enmascarado, metodo, uso, composicion farmaceutica
JPWO2013147137A1 (ja) * 2012-03-30 2015-12-14 味の素株式会社 心不全の治療剤
CZ2013783A3 (cs) 2013-10-08 2015-04-15 Zentiva, K. S Stabilní farmaceutická kompozice obsahující amlodipin a valsartan
WO2016073179A2 (fr) * 2014-10-23 2016-05-12 The Trustees Of The University Of Pennsylvania Nouvelle chronothérapie basée sur les rythmes circadiens
RU2616213C2 (ru) * 2015-07-10 2017-04-13 Государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ЮУГМУ Минздрава России) Способ коррекции дисфункции факторов врожденного и адаптивного иммунитета при хронической почечной недостаточности в эксперименте
WO2017075607A1 (fr) * 2015-10-31 2017-05-04 Io Therapeutics, Inc. Traitement des troubles du système nerveux au moyen de combinaisons d'agonistes de pxr et d'hormones thyroïdiennes
CN105287550A (zh) * 2015-11-19 2016-02-03 哈尔滨圣吉药业股份有限公司 一种缬沙坦/非洛地平复方制剂及其制备方法
MX2022013029A (es) 2020-04-17 2023-01-16 Honeybrains Llc Composiciones y metodos para el tratamiento de trastornos neuropsiquiatricos.
US20240299405A1 (en) * 2020-05-28 2024-09-12 Hangzhou Qian Biotechnology Ltd Application of atp potassium channel modifier in preparation of anti-diabetic nephropathy drug

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654372A (en) * 1986-01-10 1987-03-31 Warner-Lambert Company Method for using verapamil for treating stroke
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
IL97219A (en) * 1990-02-19 1995-12-08 Ciba Geigy Ag Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them
NZ242724A (en) 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
US5492904A (en) * 1991-05-15 1996-02-20 E. I. Du Pont De Nemours And Company Composition of angiotensin-II receptor antagonists and calcium channel blockers
WO1993017682A1 (fr) * 1992-03-04 1993-09-16 Abbott Laboratories Antagonistes des recepteurs de l'angiotensine ii
NZ253611A (en) * 1992-07-27 1996-09-25 Pfizer Polypeptide found in the venom of the agelenopsis spider and its use as a calcium channel blocker
US5264447A (en) * 1992-09-01 1993-11-23 Merck & Co., Inc. Angiotensin II antagonist
CA2125251C (fr) * 1993-06-07 2005-04-26 Yoshiyuki Inada Composition pharmaceutique pour le traitement des affections mediees par l'angiotensine ii
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
DK0634175T3 (da) * 1993-07-15 2001-04-30 Hoffmann La Roche Farmaceutisk kombination, der indeholder en hæmmer af renin-angiotensin-systemet og en endothelin-antagonist
CA2181461A1 (fr) * 1994-02-08 1995-08-17 Alica Huxley Antagonistes de l'angiotensine ii destines au traitement du glaucome normotensif
HUT76542A (en) 1994-03-17 1997-09-29 Ciba Geigy Ag Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
NZ509260A (en) 1998-07-10 2003-09-26 Novartis Ag Pharmaceutical composition containing valsartan and a calcium channel blocker

Also Published As

Publication number Publication date
HK1036758A1 (en) 2002-01-18
HK1152897A1 (en) 2012-03-16
HU229383B1 (en) 2013-11-28
NL300290I1 (fr) 2007-11-01
NO20010113L (no) 2001-03-09
SG142116A1 (en) 2008-05-28
CA2336822C (fr) 2009-11-17
TR200100062T2 (tr) 2001-06-21
KR100550167B1 (ko) 2006-02-08
CZ200187A3 (en) 2001-05-16
BE2016C011I2 (fr) 2018-12-04
NO2012013I1 (no) 2012-07-30
IL213926A0 (en) 2011-07-31
NL300800I2 (fr) 2016-07-27
CY2016006I1 (el) 2016-10-05
EP2322174A3 (fr) 2011-07-27
ZA200100232B (en) 2002-04-09
HUP0102828A2 (hu) 2002-04-29
CN1234357C (zh) 2006-01-04
NZ527598A (en) 2005-04-29
RU2012110522A (ru) 2013-09-27
BR9912021A (pt) 2001-04-03
WO2000002543A2 (fr) 2000-01-20
AU5034999A (en) 2000-02-01
SI1096932T1 (sl) 2008-04-30
SI2322174T1 (sl) 2015-12-31
DE122007000055I1 (de) 2007-12-13
HUP0102828A3 (en) 2002-11-28
CY1107779T1 (el) 2010-07-28
DK1096932T3 (da) 2007-10-15
NZ509260A (en) 2003-09-26
PT1096932E (pt) 2007-09-21
NL300290I2 (nl) 2008-11-03
SK285863B6 (sk) 2007-10-04
ES2289814T3 (es) 2008-02-01
AU753486B2 (en) 2002-10-17
EP1870098A3 (fr) 2010-07-07
FR16C0008I2 (fr) 2018-06-08
SK312001A3 (en) 2001-06-11
CY2016006I2 (el) 2016-10-05
EP1096932B1 (fr) 2007-08-29
EP1096932A2 (fr) 2001-05-09
LU91358I2 (fr) 2007-11-06
CN1312715A (zh) 2001-09-12
FR16C0008I1 (fr) 2016-04-15
DE69936992T2 (de) 2008-03-06
KR20010079517A (ko) 2001-08-22
CY1116770T1 (el) 2016-10-05
RU2243768C2 (ru) 2005-01-10
PT2322174E (pt) 2015-10-27
CY2007026I2 (el) 2009-11-04
ATE371448T1 (de) 2007-09-15
CZ299429B6 (cs) 2008-07-23
PL194604B1 (pl) 2007-06-29
NO331802B1 (no) 2012-04-10
IL140665A (en) 2012-12-31
CZ304359B6 (cs) 2014-03-26
CA2678722A1 (fr) 2000-01-20
NO2012013I2 (no) 2014-10-27
EP2322174B1 (fr) 2015-09-23
ES2552639T3 (es) 2015-12-01
EP1870098A2 (fr) 2007-12-26
CA2336822A1 (fr) 2000-01-20
CY2007026I1 (el) 2009-11-04
KR20040078140A (ko) 2004-09-08
NO20010113D0 (no) 2001-01-08
PL345897A1 (en) 2002-01-14
WO2000002543A3 (fr) 2000-06-29
LU92992I2 (fr) 2016-05-09
CA2678722C (fr) 2013-08-27
EP2322174A2 (fr) 2011-05-18
RU2450813C2 (ru) 2012-05-20
CN1733307A (zh) 2006-02-15
ID27664A (id) 2001-04-19
JP2002520274A (ja) 2002-07-09
DE69936992D1 (de) 2007-10-11
DK2322174T3 (en) 2015-10-12

Similar Documents

Publication Publication Date Title
BE2016C011I2 (fr)
NL300811I2 (fr)
EP1507558B8 (fr) Composition pharmaceutique comprenant un inhibiteur de renine, un agent de blocage du canal du calcium et un diuretique

Legal Events

Date Code Title Description
EXTE Period for filing application for extension order has been extended (section 64p.(4))
EXTE Period for filing application for extension order has been extended (section 64p.(4))